LPCN News and Press, Lipocine Inc. From 03/10/23

Lipocine Announces Financial Results for the Year Ended December 31, 2022 PR Newswire SALT LAKE CITY , March 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leverag...

Lipocine to Present at Biotech Showcase PR Newswire Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event SALT LAKE CITY , Jan. 5, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treati...

Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis PR Newswire Top-line 24-week results from proof-of-concept study expected mid-2023 SALT LAKE CITY , Dec. 19, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceu...

Lipocine press release ( NASDAQ: LPCN ): Q3 GAAP EPS of -$0.03 in-line. As of September 30, 2022, the company had $34.3 million of unrestricted cash, cash equivalents and marketable investment securities, compared to $46.6 million on December ...

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022 PR Newswire SALT LAKE CITY , Nov. 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") diso...

Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline PR Newswire SALT LAKE CITY , Nov. 3, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating CNS disorders by leveraging its p...

Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference PR Newswire SALT LAKE CITY , Oct. 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to devel...

Lipocine to Participate in the Cantor Neurology & Psychiatric Conference Lipocine to Participate in the Cantor Neurology & Psychiatric Conference PR Newswire SALT LAKE CITY , Sept. 27, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a bioph...

Lipocine ( NASDAQ: LPCN ) on Monday said the company would now focus on applying its drug delivery technology to develop treatments for central nervous system (CNS) disorders. LPCN stock +4.7% to $0.52 in premarket trading. The company will use its proprietary Lip'...

Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders PR Newswire Company to apply its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products for Central Nervous System (CNS) disorders Initial...